Articles related to MOVEMENT DISORDERS

The FDA has approved tavapadon, a selective D1/D5 dopamine receptor partial agonist, for adults with Parkinson disease following phase 3 studies demonstrating benefit both as monotherapy in early disease and as adjunctive therapy to levodopa.

Recordings from four Parkinson’s disease patients linked cuneiform and pedunculopontine nuclei activity to distinct phases of gait initiation. Freezing episodes were preceded by disrupted mesencephalic timing, though clinical translation remains early.

The first participant was dosed in a Phase 3 trial of oral votoplam, as interim Phase 2 extension data suggested dose-dependent slowing of Huntington’s progression.

The Tardive Dyskinesia Impact Scale showed high discrimination and precision across physical function and socioemotional domains in pooled data from 388 patients in the KINECT 3 and KINECT 4 valbenazine trials.

VMAT2 inhibitors were associated with lower rates of falls, injuries, fractures, and several secondary adverse outcomes than anticholinergic agents in a propensity-matched cohort of adults with tardive dyskinesia.

Switching Parkinson’s patients to Crexont added more than three hours of daily symptom control in interim Phase 4 data. Here’s how to read an open-label, sponsor-run signal.